Prognostic Value of Circulating MG53 Levels in Acute Myocardial Infarction

Area of Science:

• Cardiology
• Biomarkers
• Proteomics

Background:

• Mitsugumin 53 (MG53), a TRIM family protein, protects the heart from oxidative injury.
• Previous mouse studies showed MG53 release during cardiac ischemia, but human data was lacking.
• The prognostic significance of MG53 in human ST-segment elevation myocardial infarction (STEMI) was unknown.

Purpose of the Study:

• To evaluate the prognostic value of serum MG53 levels in patients with STEMI.
• To determine if MG53 can predict major adverse cardiovascular events (MACE) in this population.

Main Methods:

• Serum MG53 levels were measured in 300 STEMI patients.
• Patients were followed for 3 years, with MACE (cardiovascular death, heart failure rehospitalization, recurrent MI, stroke) as the primary endpoint.
• Association with baseline characteristics, cardiac function markers (LVEF, NT-pro-BNP, cTnI), and prediction of MACE were analyzed.

Main Results:

• Higher MG53 levels were associated with older age, diabetes, and poorer cardiac function indicators.
• Elevated MG53 (>132.17 pg/ml) significantly predicted MACE and was an independent predictor of cardiovascular death.
• MG53 improved risk prediction models for MACE, both alone and combined with cardiac troponin I (cTnI).

Conclusions:

• Serum MG53 is a valuable prognostic marker for MACE in acute myocardial infarction (AMI) patients.
• MG53 offers independent prognostic information beyond conventional risk factors.
• MG53 enhances risk stratification in patients following myocardial infarction.